For people at high risk of HIV, taking a daily dose of a prevention drug is essential. But many can't afford it. A new federal program makes the drugs available for free.
Knowing where rates of prevalence are highest — and lowest — can lead to new strategies for treatment and prevention. The map focuses on sub-Saharan Africa, the epicenter of the epidemic.
As head of the Department of Health and Human Services, Alex Azar is charged with making Trump's plan to end HIV in the U.S. by 2030 work. "We have an historic opportunity," he tells NPR.
The Trump administration has a plan to end the spread of HIV in the U.S. in 10 years. HIV/AIDS advocates say it's feasible but that the administration's actions on health run counter to the goal.
Many people at high risk for HIV can't afford PrEP, though it's more than 90 percent effective if taken daily. Its list price, close to $2,000 for a 30-day supply, has risen 45 percent in six years.
The idea is to inject anti-HIV antibodies that would kill the virus when people get exposed. A new study is promising — although it was conducted on monkeys.
PrEP is shorthand for a pill that prevents HIV infection, if taken daily. As Washington, D.C. aims to cut new infections in half by 2020, it hopes to quadruple the number of residents on the medicine.
Critics say it's not appropriate for a health group to work with a beer company. Others argue that such partnerships are vital to eliminate diseases like AIDS and TB by 2030.
For LGBTQ Americans in rural areas, finding a sympathetic physician can be difficult. And that challenge makes getting appropriate health care even harder.
Trials are underway to see how effective a pill approved for HIV prevention in adults may be for teenagers. But some worry Truvada could end up encouraging reckless sexual behavior among young people.
Some drug users in Philadelphia are reselling syringes they get for free at needle exchanges. That's illegal, but researchers say the practice still helps prevent the spread of diseases like HIV.
